Silicone Breast Implants: Materials, Design and Decision Factors

A silicone breast implant is a silicone elastomer shell filled with silicone gel, chosen over a saline implant mainly because gel behaves more like breast tissue — it moves more naturally, ripples less under thin skin, and holds shape more predictably. The trade is not in the operation but in what comes after it. A saline implant announces its own failure by deflating; a gel implant usually does not, which is why silicone devices come with a surveillance expectation attached. That is the part of the decision most consultations underplay. Choosing silicone is choosing a device with better behaviour and a longer-running responsibility, and both halves belong in the conversation before anything is booked.

Silicone against saline, on explicit criteria

Within silicone there are further choices — how cohesive the gel is, whether the shell is smooth or textured, and whether the device is round or shaped. Those are selected against your base width, tissue thickness and the shape you want, and the right combination differs between patients rather than following a ranking.

A breast implant is a long-term medical device

Patients think of augmentation as an event with a recovery. Silicone gel is better understood as a long-term relationship with a manufactured object placed inside living tissue. The object does not change; the tissue around it does, continuously, with age, weight, pregnancy and gravity. A capsule forms around it and can tighten years later. The shell can fail without any outward sign. None of that is a complication of poor surgery — it is what a device with a service life does.

Two consequences follow. First, over a long enough horizon a proportion of patients will have further surgery for device or tissue reasons, and a plan that does not acknowledge this has simply moved the conversation into the future. Second, the practical value of choosing silicone lies partly in the arrangements you make around it: who holds your implant records, who reviews you, and what imaging you will have. A modest device with a documented follow-up plan may be a more coherent choice than an impressive one with no route back to the person who placed it.

Monitoring, stated plainly

Because gel rupture is frequently symptomless, imaging surveillance is recommended for silicone implants — typically with ultrasound or MRI, on a schedule that varies by country, manufacturer and clinical circumstance. Ask specifically what schedule applies to your device rather than assuming one, and treat it as part of the cost of the operation.

Insist on receiving your implant documentation: manufacturer, model, size and serial numbers, recorded in your name, together with the operation note. You will need these for future imaging, for any warranty, and for whoever performs later surgery, possibly decades from now and in another country. Retrieving them retrospectively is often impossible. Mention your implants whenever you attend for breast screening, since a different technique is used to image around a device.

Risks that belong to the device rather than the operation

• Capsular contracture. The natural capsule tightens, changing shape, firmness and sometimes comfort. It can occur at any point and may require further surgery.
• Silent rupture. Shell failure without symptoms; found on imaging, managed by exchange or removal.
• Rippling and palpability. More likely where tissue cover is thin, which is a tissue matter as much as a device one.
• Implant-associated lymphoma. A rare cancer of the capsule associated with certain textured surfaces, which has changed how texturing is used. Ask why the proposed surface was selected for you.
• Systemic symptoms attributed to implants. Some patients report clusters of symptoms they associate with their devices. This remains under investigation and deserves open discussion rather than dismissal.
• Sensory change and effects on future imaging and breastfeeding. All should be covered in consent rather than discovered later.

What examination has to establish first

Base width fixes the diameter of device that fits your chest; tissue thickness determines how much of the device will be perceptible and how well it will be supported over time; nipple position relative to the fold determines whether an implant alone is the right operation or whether a lift is needed. Skin quality, asymmetry and chest-wall shape complete the picture. Photographs supply none of it, and a device recommended before you have been measured is a preference rather than a plan. Examination should also test whether an implant is the right answer at all, since fat transfer, a lift, a staged plan or no operation are legitimate outcomes of an honest assessment.

Expected recovery involves swelling, tightness and restricted activity for a period that varies between individuals, and precise universal dates overstate what can be known. An earlier clinical review is sensible for worsening pain, progressive one-sided swelling, fever, spreading redness, or new wound discharge. Prompt medical assessment is appropriate for chest pain, difficulty breathing, or new one-sided calf pain with swelling. Later, a new firm lump, unexplained one-sided swelling or a change in breast shape warrants specialist evaluation.

Questions that will tell you how considered the plan is

1. What are my base width and tissue thickness, and which devices do they permit?
2. Which manufacturer, gel cohesivity and shell surface are proposed, and why those?
3. Will I leave with implant documentation recorded in my name?
4. What imaging surveillance applies to this device, and starting when?
5. What warranty does the manufacturer provide, and what does it exclude?
6. What would need to be different about my anatomy for you to recommend saline, or a different gel?
7. How is follow-up handled at six months and beyond?

Pocket, incision and profile decisions are set out alongside device selection on the breast augmentation page. The sensible next step is an examination in which the device is chosen last, after measurement, and in which the monitoring plan is agreed at the same time as the implant — because those two decisions are genuinely one decision.